Projects per year
Personal profile
Personal profile
Dr. Jenny C. Chang is the Director of Houston Methodist Cancer Center and Emily Herrmann Chair in Cancer Research in Houston, Texas. She obtained her medical degree at Cambridge University in England, and then completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research in the United Kingdom. She was also awarded a research doctorate from the University of London. Her recent work has focused on the intrinsic therapy resistance of cancer stem cells, which has led to several publications and international presentations. Dr. Chang’s clinical research aims to evaluate novel biologic agents in breast cancer patients.
Research interests
Dr. Chang has worked in the field of tumor-initiating cells for more than ten years. After her discovery that tumor-initiating cells are chemo-resistant, and that targeting the EGFR/HER2 pathway can decrease this subpopulation, Dr. Chang has played a key role in demonstrating some of the limitations and mechanisms of tumor-initiating cells (Creighton et al., 2009; Li et al., 2008). Her work is now focused on the mechanisms that regulate TICs, as well as initiating and planning clinical trials that target this critical tumor initiating subpopulation. She is also interested in characterizing the cross-talk between these different pathways that may lead to mechanisms of resistance, and has identified some of the chief regulatory pathways involved in TIC self-renewal. She is a world-renown clinical investigator, credited as one of the first to describe intrinsic chemo-resistance of tumor-initiating cells.
Education/Academic qualification
MD, University of Cambridge
Aug 1 1986 → Dec 18 1990
Award Date: Dec 18 1990
Research Doctorate, University of London
External positions
Professor of Medicine, Weill Cornell Medical College, Cornell University
Research Area Keywords
- Cancer
- Systems Medicine & Bioinformatics
- Clinical Translation & Trials
Free-text keywords
- Cancer
- Stem cells
- Breast cancer
- High throughput
Fingerprint
- 12 Similar Profiles
Network
Projects
-
COVID- Tocilizumab, Anakinra and Infliximab
Chang, J. C., Darcourt, J., Ensor, Jr., J. E., Masud, F. N., Niravath, P. A., Pingali, S. R., Randhawa, J. & Zainab, A.
12/4/20 → …
Project: Clinical Trial
-
A011502 ABC STUDY CIRB SUBMISSION
Arentz, C., Chang, J. C., Darcourt, J., Heyne, K., Niravath, P. A. & Singh, M.
11/17/20 → …
Project: Clinical Trial
-
Phase III_OlanzapineFosaprepitant_Highly Emetogenic Chemotherapy Patients_ALLIANCE A221602
Darcourt, J., Bernicker, E. H., Chang, J. C., Geyer, C. E., Heyne, K., Niravath, P. A. & Randhawa, J.
9/28/20 → …
Project: Clinical Trial
-
Spatiotemporal modeling of cancer-niche interactions in breast cancer bone metastasis
Wong, S. T., Chang, J. C. & Sheng, J.
9/15/20 → 8/31/25
Project: Federal Funding Agencies
Research Output
-
Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma
Li, Z., Liu, H., He, J., Wang, Z., Yin, Z., You, G., Wang, Z., Davis, R. E., Lin, P., Bergsagel, P. L., Manasanch, E. E., Wong, S. T. C., Esnaola, N. F., Chang, J. C., Orlowski, R. Z., Yi, Q. & Yang, J., Jan 5 2021, In : Cell Metabolism. 33, 1, p. 78-93.e7Research output: Contribution to journal › Article
Open Access -
A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations
Reddy, T. P., Rosato, R. R., Li, X., Moulder, S., Piwnica-Worms, H. & Chang, J. C., Dec 1 2020, In : Breast Cancer Research. 22, 1, 121.Research output: Contribution to journal › Review article
Open Access -
A Deep Learning-Based Decision Support Tool for Precision Risk Assessment of Breast Cancer
He, T., Puppala, M., Ezeana, C. F., Huang, Y-S., Chou, P-H., Yu, X., Chen, S., Wang, L., Yin, Z., Danforth, R. L., Ensor, J., Chang, J., Patel, T. & Wong, S. T. C., Jan 2020, In : JCO Clinical Cancer Informatics. 3, p. 1-12 12 p.Research output: Contribution to journal › Article
9 Scopus citations -
A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer
Anand, K., Niravath, P. A., Patel, T., Ensor, J., Rodriguez, A. A., Boone, T., Wong, S. T. & Chang, J. C., 2020, (Accepted/In press) In : Clinical Breast Cancer.Research output: Contribution to journal › Article
1 Scopus citations -
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
Goldstein, L. J., Perez, R. P., Yardley, D., Han, L. K., Reuben, J. M., Gao, H., McCanna, S., Butler, B., Ruffini, P. A., Liu, Y., Rosato, R. R. & Chang, J. C., Jan 10 2020, In : Breast Cancer Research. 22, 1, 4.Research output: Contribution to journal › Article
3 Scopus citations